HIV and the heart: The impact of antiretroviral therapy: A global perspective

European Heart Journal

Volumn 34, Issue 46, 2013, Pages

  Thienemann, Friedrich ^a,b   Sliwa, Karen ^b,c   Rockstroh, Jürgen Kurt ^d  

^a Faculty of Health Sciences   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Abacavir; Antiretroviral therapy; ART; Cardiomyopathy; Cardiovascular; Heart; HIV; Pericarditis; Protease inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DEVELOPING COUNTRY; DIABETES MELLITUS; ECG ABNORMALITY; GLUCOSE METABOLISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; LIFESTYLE MODIFICATION; NONHUMAN; PERICARDIAL DISEASE; PERICARDITIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SOCIAL STATUS; TUBERCULOSIS;

ABACAVIR; ANTIRETROVIRAL THERAPY; ART; CARDIOMYOPATHY; CARDIOVASCULAR; HEART; HIV; PERICARDITIS; PROTEASE INHIBITORS;

ANTI-HIV AGENTS; CARDIOMYOPATHIES; COINFECTION; CORONARY ARTERY DISEASE; DIABETIC ANGIOPATHIES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HEART DISEASES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; HYPERTENSION, PULMONARY; IMMUNOSUPPRESSION; PERICARDITIS; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; RISK REDUCTION BEHAVIOR; TUBERCULOSIS; WORLD HEALTH;

EID: 84890962877     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht388     Document Type: Review

References (94)

1. May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, Justice AC, Dabis F, Gill J, Lundgren J,Hogg RS, deWolf F, Fatkenheuer G, Staszewski S, d'Arminio Monforte A, Egger M. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 2006;368: 451-458.
2. Lewden C, Chene G, Morlat P, Raffi F, Dupon M, Dellamonica P, Pellegrin JL, Katlama C, Dabis F, Leport C. HIV-infected adults with a cd4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007;46: 72-77. (Pubitemid 47514615)
3. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York city. Ann Int Med 2006;145: 397-406. (Pubitemid 46768570)
4. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, Thiebaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, Lundgren JD. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349: 1993-2003.
5. Syed FF, Sani MU. Recent advances in HIV-associated cardiovascular diseases in Africa. Heart 2013;99: 1146-1153.
6. Bloomfield GS, Barasa FA, Doll JA, Velazquez EJ. Heart failure in sub-Saharan Africa. Curr Cardiol Rev 2013;9: 157-173.
7. Ntsekhe M, Hakim J. Impact of human immunodeficiency virus infection on cardiovascular disease in Africa. Circulation 2005;112: 3602-3607. (Pubitemid 43739538)
8. Ntsekhe M, Mayosi BM. Cardiac manifestations of HIV infection: an African perspective. Nat Clin Pract Cardiovasc Med 2009;6: 120-127.
9. Sliwa K, Carrington MJ, Becker A, Thienemann F, Ntsekhe M, Stewart S. Contribution of the human immunodeficiency virus/acquired immunodeficiency syndrome epidemic to de novo presentations of heart disease in the heart of SOWETO study cohort. Eur Heart J 2012;33: 866-874.
10. Young J, Psichogiou M, Meyer L, Ayayi S, Grabar S, Raffi F, Reiss P, Gazzard B, Sharland M, Gutierrez F, Obel N, Kirk O, Miro JM, Furrer H, Castagna A, De Wit S, Munoz J, Kjaer J, Grarup J, Chene G, Bucher H. Cd4 cell count and the risk of aids or death in HIV-infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from cohere. PLoS Med 2012;9: e1001194.
11. UNAIDS. Joint united nations program on HIV/AIDS and world health organization: unaids report on the global aids epidemic. 2009.
12. Heidenreich PA, Eisenberg MJ, Kee LL, Somelofski CA, Hollander H, Schiller NB, Cheitlin MD. Pericardial effusion in AIDS. Incidence and survival. Circulation 1995; 92: 3229-3234.
13. Cegielski JP, Ramiya K, Lallinger GJ, Mtulia IA, Mbaga IM. Pericardial disease and human immunodeficiency virus in dar es salaam, Tanzania. Lancet 1990;335: 209-212. (Pubitemid 20054588)
14. Stotka JL, Good CB, Downer WR, Kapoor WN.Pericardial effusion and tamponade due to Kaposi's sarcoma in acquired immunodeficiency syndrome. Chest 1989;95: 1359-1361. (Pubitemid 19160180)
15. Karve MM, Murali MR, Shah HM, Phelps KR. Rapid evolution of cardiac tamponade due to bacterial pericarditis in two patients with HIV-1 infection. Chest 1992;101: 1461-1463.
16. Aggarwal P, Sharma A, Bhardwaj R, Raina R. Myocardial dysfunction in human immunodeficiency virus infection: an echocardiographic study. J Assoc Physicians India 2009;57: 745-746.
17. Hakim JG, Matenga JA, Siziya S. Myocardial dysfunction in human immunodeficiency virus infection: an echocardiographic study of 157 patients in hospital in Zimbabwe. Heart 1996;76: 161-165. (Pubitemid 26258744)
18. Guha S, Pande A, Mookerjee S, Bhattacharya R, Pain S, Karmakar RN, Mani S, Bhattacharya R, Biswas A, Hema, Saha S, Deb PK. Echocardiographic profile of art naive human immunodeficiency virus (HIV) infected patients in a tertiary care hospital in Kolkata. Indian Heart J 2010;62: 330-334.
19. Barbaro G. Cardiovascular manifestations of HIV infection. Circulation 2002;106: 1420-1425. (Pubitemid 35013048)
20. Hsia J, Ross AM. Pericardial effusion and pericardiocentesis in human immunodeficiency virus infection. Am J Cardiol 1994;74: 94-96. (Pubitemid 24196325)
21. Flum DR, McGinn JT Jr, Tyras DH. The role of the 'pericardial window' in AIDS. Chest 1995;107: 1522-1525.
22. Chen Y, Brennessel D,Walters J, Johnson M, Rosner F, Raza M. Human immunodeficiency virus-associated pericardial effusion: report of 40 cases and review of the literature. Am Heart J 1999;137: 516-521. (Pubitemid 29124121)
23. Lind A, Reinsch N, Neuhaus K, Esser S, Brockmeyer NH, Potthoff A, Pankuweit S, Erbel R, Maisch B, Neumann T. Pericardial effusion of HIV-infected patients? Results of a prospective multicenter cohort study in the era of antiretroviral therapy. Eur J Med Res 2011;16: 480-483.
24. Cegielski JP, Lwakatare J, Dukes CS, Lema LE, Lallinger GJ, Kitinya J, Reller LB, Sheriff F. Tuberculous pericarditis in Tanzanian patients with and without HIV infection. Tuber Lung Dis 1994;75: 429-434.
25. Longo-Mbenza B, Tonduangu K, Seghers KV, Mubagwa D. HIV infection and pericardial disease invasion in Africa. Arch Mal Coeur Vaiss 1997;90: 1377-1384. (Pubitemid 27466029)
26. Taelman H, Kagame A, Batungwanayo J, Nyirabareja A, Abdel Aziz M, Blanche P, Bogaerts J, van de Perre P. Pericardial effusion and HIV infection. Lancet 1990;335: 924. (Pubitemid 20136835)
27. Anderson DW, Virmani R, Reilly JM, O'Leary T, Cunnion RE, Robinowitz M, Macher AM, Punja U, Villaflor ST, Parrillo JE, Roberts WC. Prevalent myocarditis at necropsy in the acquired immunodeficiency syndrome. J Am Coll Cardiol 1988; 11: 792-799. (Pubitemid 18092188)
28. Barbaro G, Di Lorenzo G, Grisorio B, Barbarini G. Incidence of dilated cardiomyopathy and detection of hiv in myocardial cells of HIV-positive patients. Gruppo italiano per lo studio cardiologico dei pazienti affetti da aids. N Engl J Med 1998;339: 1093-1099. (Pubitemid 28465756)
29. Mayosi BM. Contemporary trends in the epidemiology and management of cardiomyopathy and pericarditis in sub-Saharan Africa. Heart 2007;93: 1176-1183. (Pubitemid 47492897)
30. WHO. World health organization: Case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. 2007.
31. Barbaro G, Di Lorenzo G, Soldini M, Giancaspro G, Grisorio B, Pellicelli A, Barbarini G. Intensity of myocardial expression of inducible nitric oxide synthase influences the clinical course of human immunodeficiency virus-associated cardiomyopathy. gruppo italiano per lo studio cardiologico dei pazienti affetti da aids (gisca). Circulation 1999;100: 933-939. (Pubitemid 29407173)
32. Currie PF, Jacob AJ, Foreman AR, Elton RA, Brettle RP, Boon NA. Heart muscle disease related to HIV infection: prognostic implications. BMJ 1994;309: 1605-1607.
33. Twagirumukiza M, Nkeramihigo E, Seminega B, Gasakure E, Boccara F, Barbaro G. Prevalence of dilated cardiomyopathy in HIV-infected African patients not receiving HAART: a multicenter, observational, prospective, cohort study in Rwanda. Curr HIV Res 2007;5: 129-137. (Pubitemid 46062366)
34. Nzuobontane D, Blackett KN, Kuaban C. Cardiac involvement in HIV infected people in Yaounde, Cameroon. Postgrad Med J 2002;78: 678-681. (Pubitemid 36090112)
35. Luo L, YeY, Liu Z, Zuo L, Li Y, Han Y, Qiu Z, Li L, Zeng Y, Li TS. Assessment of cardiac diastolic dysfunction in HIV-infected people without cardiovascular symptoms in China. Int J STD AIDS 2010;21: 814-818.
36. Jain N, Reddy DH, Verma SP, Khanna R, Vaish AK, Usman K, Tripathi AK, Singh A, Mehrotra S, Gupta A. Cardiac abnormalities in HIV-positive patients: results from an observational study in India. J Int Assoc Physicians AIDS Care (Chic); doi: 10.1177/1545109712456740. Published online ahead of print 11 September 2012.
37. Barbaro G, Barbarini G. Human immunodeficiency virus and cardiovascular risk. Indian J Med Res 2011;134: 898-903.
38. Bijl M, Dieleman JP, Simoons M, van der Ende ME. Low prevalence of cardiac abnormalities in an HIV-seropositive population on antiretroviral combination therapy. J Acquir Immune Defic Syndr 2001;27: 318-320. (Pubitemid 32661978)
39. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Simonneau G. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173: 1023-1030.
40. Zuber JP, Calmy A, Evison JM, Hasse B, Schiffer V,Wagels T, Nuesch R, Magenta L, Ledergerber B, Jenni R, Speich R, Opravil M. Pulmonary arterial hypertension related to HIV infection: improvedhemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis 2004;38: 1178-1185. (Pubitemid 38951268)
41. Sitbon O, Lascoux-Combe C,Delfraissy JF, Yeni PG, Raffi F,DeZuttere D, GressinV, Clerson P, Sereni D, Simonneau G. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008;177: 108-113.
42. Mehta NJ, Khan IA, Mehta RN, Sepkowitz DA. HIV-related pulmonary hypertension: analytic review of 131 cases. Chest 2000;118: 1133-1141.
43. Almodovar S, Cicalini S, Petrosillo N, Flores SC. Pulmonary hypertension associated with HIV infection: pulmonary vascular disease: the global perspective. Chest 2010; 137:6S-12S.
44. Opravil M, Sereni D. Natural history of HIV-associated pulmonary arterial hypertension: trends in the HAART era. AIDS (London, England) 2008;22(Suppl. 3):S35-S40.
45. Olusegun-Joseph DA, Ajuluchukwu JN, Okany CC, Mbakwem AC, Oke DA, Okubadejo NU. Echocardiographic patterns in treatment-naive HIV-positive patients in Lagos, south-west Nigeria. Cardiovasc J Afr 2012;23:e1-e6.
46. Degano B, Guillaume M, Savale L, Montani D, Jais X, Yaici A, Le Pavec J, Humbert M, Simonneau G, Sitbon O. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. AIDS (London, England) 2010;24: 67-75.
47. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT, Levy PS, Pietra GG, Reid LM, Reeves JT, Rich S, Vreim CE, Williams GW, Wu M. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Int Med 1991;115: 343-349.
48. Nunes H, Humbert M, Sitbon O, Morse JH, Deng Z, Knowles JA, Le Gall C, Parent F, Garcia G, Herve P, Barst RJ, Simonneau G. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003;167: 1433-1439. (Pubitemid 36609730)
49. Baker JV, Lundgren JD. Cardiovascular implications from untreated human immunodeficiency virus infection. Eur Heart J 2011;32: 945-951.
50. Chi D, Henry J, Kelley J, Thorpe R, Smith JK, Krishnaswamy G. The effects of hiv infection on endothelial function. Endothelium 2000;7: 223-242. (Pubitemid 32015782)
51. Becker AC, Sliwa K, Stewart S, Libhaber E, Essop AR, Zambakides CA, Essop MR. Acute coronary syndromes in treatment-naive black South Africans with human immunodeficiency virus infection. J Interv Cardiol 2010;23: 70-77.
52. BeckerAC, Jacobson B, Singh S, Sliwa K, Stewart S, Libhaber E, Essop MR. The thrombotic profile of treatment-naive HIV-positive black South Africans with acute coronary syndromes. Clin Appl Thromb/Hemos 2011;17: 264-272.
53. Lopez M, San Roman J, Estrada V, Vispo E, Blanco F, Soriano V. Endothelial dysfunction in HIV infection: the role of circulating endothelial cells, microparticles, endothelial progenitor cells and macrophages. AIDS Rev 2012;14: 223-230.
54. Stewart S, Carrington M, Pretorius S, Methusi P, Sliwa K. Standing at the crossroads between new and historically prevalent heart disease: effects of migration and socioeconomic factors in the heart of SOWETO cohort study. Eur Heart J 2011;32: 492-499.
55. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part ii: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 2001;104: 2855-2864. (Pubitemid 33126663)
56. Vilela FD, Lorenzo AR, Tura BR, Ferraiuoli GI, Hadlich M, Barros MV, Lima AB, Meirelles V. Risk of coronary artery disease in individuals infected with human immunodeficiency virus. Brazil J Infect Dis 2011;15: 521-527.
57. Stewart S, Wilkinson D, Hansen C, Vaghela V, Mvungi R, McMurray J, Sliwa K. Predominance of heart failure in the heart of SOWETO study cohort: emerging challenges for urban African communities. Circulation 2008;118: 2360-2367.
58. Tibazarwa K, Ntyintyane L, Sliwa K, Gerntholtz T, Carrington M, Wilkinson D, Stewart S. A time bomb of cardiovascular risk factors in South Africa: results from the heart of soweto study "heart awareness days". Int J Cardiol 2009;132: 233-239.
59. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007;92: 2506-2512. (Pubitemid 47037350)
60. Esser S, Gelbrich G, Brockmeyer N, Goehler A, Schadendorf D, Erbel R, NeumannT, Reinsch N. Prevalence of cardiovascular diseases in HIV-infected outpatients: results from a prospective, multicenter cohort study. Clin Res Cardiol 2013;102: 203-213.
61. Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med 2012;13: 453-468.
62. Smith C, Sabin CA, Lundgren JD, Thiebaut R,Weber R, Law M, Monforte A, Kirk O, Friis-Moller N, Phillips A, Reiss P, El Sadr W, Pradier C, Worm SW. Factors associated with specific causes of death amongst HIV-positive individuals in the d:A:D study. AIDS (London, England) 2010;24: 1537-1548.
63. Duprez DA, Kuller LH, Tracy R, Otvos J, Cooper DA, Hoy J, Neuhaus J, Paton NI, Friis-Moller N, Lampe F, Liappis AP, Neaton JD. Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Atherosclerosis 2009;207: 524-529.
64. Friis-Moller N, Reiss P, Sabin CA,Weber R, Monforte A, El-SadrW, Thiebaut R, De Wit S, Kirk O, Fontas E, LawMG, Phillips A, Lundgren JD. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356: 1723-1735. (Pubitemid 46658704)
65. Holmberg SD, Moorman AC, Williamson JM, Tong TC, Ward DJ, Wood KC, Greenberg AE, Janssen RS. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002;360: 1747-1748. (Pubitemid 35447907)
66. Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, Boccara F, Costagliola D. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French hospital database on HIV ANRS cohort co4. Arch Inter Med 2010;170: 1228-1238.
67. Monforte A, Reiss P, Ryom L, El-SadrW, Dabis F, De Wit S,Worm SW, Law MG, Weber R, Kirk O, Pradier C, Phillips AN, Lundgren JD, Sabin CA. Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events. AIDS (London, England) 2013;27: 407-415.
68. Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D'Arminio Monforte A, Friis-Moller N, Kirk O, Pradier C, Weller I, Phillips AN, Lundgren JD. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the d:A:D study: a multi-cohort collaboration. Lancet 2008;371: 1417-1426.
69. Ding X, Andraca-Carrera E, Cooper C, Miele P, Kornegay C, Soukup M, Marcus KA. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr 2012;61: 441-447.
70. Tanuma J, Ishizaki A, Gatanaga H, Kikuchi Y, Kimura S, Hiroe M, Oka S. Dilated cardiomyopathy in an adult human immunodeficiency virus type 1-positive patient treated with a zidovudine-containing antiretroviral regimen. Clin Infect Dis 2003; 37:e109-e111.
71. Herskowitz A, Willoughby SB, Baughman KL, Schulman SP, Bartlett JD. Cardiomyopathy associated with antiretroviral therapy in patients with HIV infection: a report of six cases. Ann Intern Med 1992;116: 311-313.
72. CardosoJS, Moura B, Mota-Miranda A, Goncalves FR, Lecour H. Zidovudine therapy and left ventricular function and mass in human immunodeficiency virus-infected patients. Cardiology 1997;88: 26-28. (Pubitemid 26400309)
73. Cardoso JS, Moura B, Martins L, Mota-Miranda A, Rocha Goncalves F, Lecour H. Left ventricular dysfunction inhuman immunodeficiency virus (HIV)-infected patients. Int J Cardiol 1998;63: 37-45. (Pubitemid 28060224)
74. Jacob AJ, Sutherland GR, Bird AG, Brettle RP, Ludlam CA, McMillan A, Boon NA. Myocardial dysfunction in patients infected with HIV: prevalence and risk factors. Br Heart J 1992;68: 549-553. (Pubitemid 23001730)
75. Berry C, Tardif JC, Bourassa MG. Coronary heart disease in patients with diabetes: part I: recent advances in prevention and noninvasive management. J Am Coll Cardiol 2007;49: 631-642. (Pubitemid 46205041)
76. Butt AA, McGinnis K, Rodriguez-Barradas MC, Crystal S, Simberkoff M, Goetz MB, Leaf D, Justice AC. HIV infection and the risk of diabetes mellitus. AIDS (London, England) 2009;23: 1227-1234.
77. Kalra S, Agrawal N. Diabetes and HIV: current understanding and future perspectives. Curr Diab Rep 2013;13: 419-427.
78. Butt AA, Fultz SL, Kwoh CK, Kelley D, SkandersonM, Justice AC. Risk of diabetes in HIV infected veterans pre- and post-HAART and the role ofHCVcoinfection. Hepatology 2004;40: 115-119. (Pubitemid 38868929)
79. BrownTT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, Visscher BR, Margolick JB, Dobs AS. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter aids cohort study. Arch Inter Med 2005;165: 1179-1184. (Pubitemid 40720744)
80. Brown TT, Glesby MJ. Management of the metabolic effects of HIV and HIV drugs. Nat Rev Endocrinol 2012;8: 11-21.
81. Grunfeld C. Insulin resistance in HIV infection: drugs, host responses, or restoration to health? Topics HIV Med 2008;16: 89-93.
82. Blumer RM, van Vonderen MG, Sutinen J, Hassink E, Ackermans M, van Agtmael MA, Yki-Jarvinen H, Danner SA, Reiss P, Sauerwein HP. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy. AIDS (London, England) 2008;22: 227-236.
83. Fleischman A, Johnsen S, Systrom DM, Hrovat M, Farrar CT, Frontera W, Fitch K, Thomas BJ, Torriani M, Cote HC, Grinspoon SK. Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. Am J Physiol Endocrinol Metab 2007;292: E1666-E1673. (Pubitemid 47084702)
84. Lorgis L, Cottenet J, Molins G, Benzenine E, Zeller M, Aube H, Touzery C, Hamblin J, Gudjoncik A, Cottin Y, Quantin C. Outcomes after acute myocardial infarction in HIV-infected patients: analysis of data from a French nationwide hospital medical information database. Circulation 2013;127: 1767-1774.
85. Soliman EZ, Prineas RJ, RoedigerMP, Duprez DA, Boccara F, Boesecke C, Stephan C, Hodder S, Stein JH, Lundgren JD, Neaton JD. Prevalence and prognostic significance of ECG abnormalities in HIV-infected patients: results from the strategies for management of antiretroviral therapy study. J Electrocardiol 2011;44: 779-785.
86. Sani MU, Okeahialam BN.QTCinterval prolongation in patients with HIV and AIDS. J Natl Med Assoc 2005;97: 1657-1661. (Pubitemid 41753112)
87. Kocheril AG, Bokhari SA, BatsfordWP, Sinusas AJ. Long qtc and torsades de pointes in human immunodeficiency virus disease. Pac Clin Electrophysiol 1997;20: 2810-2816.
88. Reinsch N, Buhr C, Krings P, Kaelsch H, Neuhaus K, WienekeH, Erbel R, NeumannT. Prevalence and risk factors of prolonged QTC interval in HIV-infected patients: results of the HIV-heart study. HIV Clin Trial 2009;10: 261-268.
89. Fiorentini A, Petrosillo N, Di Stefano A, Cicalini S, Borgognoni L, Boumis E, Tubani L, Chinello P. Qtc interval prolongation in HIV-infected patients: a case-control study by 24-hour holter ECG recording. BMC Cardiovasc Disord 2012;12:124.
90. Anson BD,Weaver JG, Ackerman MJ, Akinsete O, Henry K, January CT, Badley AD. Blockade of herg channels by HIV protease inhibitors. Lancet 2005;365: 682-686. (Pubitemid 40260891)
91. FDA. Food and drug administration: Invirase package insert. 2010.
92. Castillo R, Pedalino RP, El-Sherif N, Turitto G. Efavirenz- associatedQTprolongation and torsade de pointes arrhythmia. Ann Pharmacother 2002;36: 1006-1008.
93. Calvo-Sanchez M, Perello R, Perez I, Mateo MG, Junyent M, Laguno M, Blanco JL, Martinez-Rebollar M, Sanchez M, Mallolas J, Gatell JM, Domingo P, Martinez E. Differences between HIV-infected and uninfected adults in the contributions of smoking, diabetes and hypertension to acute coronary syndrome: two parallel casecontrol studies. HIV Med 2013;14: 40-48.
94. O'Brien M, Montenont E, Hu L, Nardi MA, Valdes V, Merolla M, Gettenberg G, Cavanagh K, Aberg JA, Bhardwaj N, Berger JS. Aspirin attenuates platelet activation and immune activation in HIV-infected subjects on antiretroviral therapy: a pilot study. J Acquir Immune Defic Syndr 2013;63: 280-288.